Levi & Korsinsky, LLP announces that a FLGT class action lawsuit has been filed on behalf of investors who purchased Fulgent Genetics, Inc. (FLGT) securities between March 22, 2019 and August 4, 2022. For more on the FLGT Lawsuit please contact us today.
According to the Fulgent Genetics, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(i) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent’s revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; (iv) the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Fulgent Genetics, Inc. you have until November 21, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.